Published Online: 2024 October 8

Systematic Review



The Effectiveness and Safety of Rhomboid Intercostal Block for Postoperative Pain Management in Thoracic and Breast Surgical Procedures: A Meta-analysis

Taufik Saputra (¹, ^{*}, Doso Sutiyono ², Widya Istanto Nurcahyo ²

¹ Faculty of Medicine, Diponegoro University, Semarang, Indonesia

² Department of Anesthesiology and Intensive Care, Dr. Kariadi General Hospital, Faculty of Medicine, Diponegoro University, Semarang, Indonesia

*Corresponding Author: Faculty of Medicine, Diponegoro University, Semarang, Indonesia. Email: taufiksaputra99@gmail.com

Received: 17 July, 2024; Revised: 20 August, 2024; Accepted: 31 August, 2024

Abstract

Background: The rhomboid intercostal block (RIB) is an emerging regional anesthesia (RA) technique used for pain control following thoracic and breast surgery. However, comprehensive documentation on its effectiveness and safety profile remains limited. This study aims to assess the effectiveness and safety of RIB in thoracic and breast surgical procedures.

Methods: A study search was conducted following PRISMA 2020 guidelines in PubMed, Cochrane Library, Embase, Scopus, and ProQuest from 2016 to 2023 to identify randomized controlled trials (RCTs) evaluating the effectiveness and safety of RIB in thoracic and breast surgeries. The primary outcome was patient pain scores at rest, recorded at one, six, 12, and 24 hours post-surgery. Secondary outcomes included 24-hour opioid consumption and rates of postoperative nausea and vomiting (PONV).

Results: This meta-analysis included five RCTs with a total of 368 patients. Rhomboid intercostal block led to a significant reduction in NRS scores one hour post-surgery (SMD = -1.33; 95% CI = -1.74 to -0.91; P < 0.00001, I² = 18%, P = 0.27), 12 hours post-surgery (SMD = -0.74; 95% CI = -0.99 to -0.48; P < 0.00001, I² = 36%, P = 0.21), and 24 hours post-surgery (SMD = -1.62; 95% CI = -2.56 to -0.69; P = 0.0006, I² = 91%, P < 0.00001). Regarding secondary outcomes, the RIB group showed a significant reduction in 24-hour opioid consumption (SMD = -4.49; 95% CI = -6.09 to -2.90; P < 0.00001, I² = 95%, P < 0.00001) and PONV rates (RR = 0.29; 95% CI = 0.18 to 0.47; P < 0.00001, I² = 0%, P = 0.88).

Conclusions: Rhomboid intercostal block provides effective pain reduction and lowers opioid consumption within 24 hours post-surgery, while also minimizing PONV rates.

Keywords: Breast Surgery, Opioid Consumption, Pain Score, PONV, Rhomboid Intercostal Block, Thoracic Surgery

1. Background

Postoperative pain is one of the most common concerns following thoracic and breast surgical procedures (1, 2). This pain may arise from various mechanisms, including inflammatory, visceral, or somatic sources (3). Over 80% of patients experience acute postoperative pain, with around 75% describing their pain as moderate to extreme. Unrelieved postoperative pain can significantly impact quality of life, hinder functional recovery, and increase the risk of postsurgical complications. Therefore, developing effective strategies for managing postoperative pain is crucial for improving patient outcomes (1, 4). Opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used in pain management strategies, but their side effects can limit their use. Modern approaches to pain management emphasize a multimodal strategy, aiming to reduce opioid reliance, with regional anesthesia (RA) playing a central role (3, 5). Various RA techniques, such as intercostal nerve blocks, paravertebral blocks, and thoracic epidural anesthesia, are utilized to reduce postoperative pain. However, the analgesic effects of intercostal nerve blocks are short-lived, and paravertebral blocks and thoracic epidurals can lead to parasympathetic symptoms such as hypotension and bradycardia (6).

Copyright © 2024, Saputra et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

In 2016, Elsharkawy et al. introduced a novel RA technique known as the rhomboid intercostal block (RIB) (7). Rhomboid intercostal block involves injecting a local anesthetic into the upper intercostal muscle plane beneath the rhomboid muscles, providing analgesia to both the anterior and posterior thorax (Figure 1) (8). In recent years, several randomized controlled trials (RCTs) have examined the efficacy of RIB in thoracic and breast surgeries. Despite this, comprehensive documentation regarding the postoperative pain outcomes and safety profile of this technique remains limited.

2. Objectives

To address this gap, we conducted a systematic review and meta-analysis to thoroughly evaluate the efficacy and safety of RIB.

3. Methods

Under the guidelines of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement, this study evaluated the effectiveness and safety of the RIB for analgesia in thoracic and breast surgical procedures (10).

3.1. Search Strategy

A comprehensive systematic literature search was conducted using PubMed, Cochrane Library, Embase, Scopus, and ProQuest from 2016 to 2023. The search, performed until October 30, 2023, utilized primary keywords and related terms such as "rhomboid intercostal block," "rhomboid intercostal nerve block," "thoracic surgery," and "breast surgery" in various combinations. These were selected according to the PICO framework, detailed as follows:

P (population): Patients undergoing thoracic or breast surgery; I (intervention): Rhomboid intercostal block for thoracic or breast surgery; C (control): No block or placebo; O (outcomes); primary: Comparison of Numerical Rating Scale (NRS) scores; secondary: Comparison of 24-hour opioid consumption and postoperative nausea and vomiting (PONV)

The inclusion criteria were as follows: (1) RCTs; (2) population of 15 years old and older; (3) patients undergoing thoracic or breast surgery; (4) an experimental group treated with a single-shot RIB and a control group with no block; and (5) full-text publications of human studies written in English.

The exclusion criteria were: (1) non-RCTs, such as reviews, case reports, animal experiments, and in vitro

studies; (2) studies where RIB was not mentioned; and (3) studies with no control group.

3.2. Study Extraction

The titles and abstracts of all publications identified through the search were independently reviewed by TS (the primary reviewer) and DS (the secondary reviewer). Full-text copies of all studies deemed potentially eligible were obtained. After reviewing the full texts, the reviewers reassessed the studies and applied the eligibility criteria to exclude additional papers. Any disagreements were resolved through repeated discussions until consensus was reached. In cases where the two reviewers could not reach an agreement, a third reviewer (WIN) provided the final decision. Once a final consensus was achieved, the data extraction sheet was completed. The extraction form included details such as the first author, year of publication, study design, type of surgery, number of patients enrolled in each surgery type, intervention performed, and reported outcomes.

3.3. Risk of Bias Assessment

All studies included in this systematic review and meta-analysis were evaluated for risk of bias based on their study design. Two investigators (TS, DS) independently assessed each study, using the updated cochrane risk of bias tool for randomized trials (RoB 2.0) (11). In cases where different scores were assigned, any discrepancies were resolved through discussion until consensus was reached.

3.4. Quality of Evidence

The grades of recommendation, assessment, development, and evaluation (GRADE) guidelines were applied to assess the quality of evidence for each individual outcome (12). Grades of recommendation, assessment, development, and evaluation evaluates five key categories—risk of bias, imprecision, inconsistency, indirectness, and publication bias—to determine factors that may impact the quality of evidence. Based on these factors, the quality of evidence for each outcome was classified into one of four levels: high, moderate, low, or very low.

3.5. Primary and Secondary Outcomes

Postoperative NRS scores at rest, recorded at one, six, 12, and 24 hours after surgery, served as the primary outcomes. Secondary outcomes included 24-hour postoperative opioid consumption and the incidence of PONV.



Figure 1. A, the corresponding ultrasound image; B, schematic illustration showing the surrounding structures and needle position for performing the rhomboid intercostal injection at the T5 and T6 levels. IM, intercostal muscles; LA, local anesthetic; RM, rhomboid major muscle; Trap, trapezius muscle. Reproduced from Elsharkawy H, Hamadnalla H, Altinpulluk EY, Gabriel RA. Rhomboid intercostal and subservatus plane block -a case series. Korean J Anesthesiol. 2020 Dec 1;73(6):550-6 (9).

3.6. Statistical Analysis

The data extracted by the two investigators was crosschecked for accuracy. Review Manager version 5.4 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) was used to analyze the extracted data. For dichotomous data, relative risk (RR) and 95% confidence intervals (CIs) were calculated, while continuous variables were assessed using standardized mean difference (SMD) and 95% CIs. The Cochrane I² statistic employed was to assess statistical heterogeneity. Random effect models were applied in cases of significant heterogeneity ($I^2 > 50\%$); otherwise, fixed effect models were used (13, 14). Statistical significance for all outcomes was set at P < 0.05 with 95% CIs.

4. Results

After conducting a database search that initially generated 275 records, we reviewed the summaries of those records to assess eligibility. Following a filtering process to remove duplicates, 194 unique articles remained. After title and abstract screening, 16 studies were selected for full-text review. Further screening led to the exclusion of 11 studies for various reasons, leaving five eligible studies from databases and registers. These five trials included a total of 368 patients, with 184 assigned to the RIB group and 184 in the control group without blocks (6, 15-18) Figure 2 presents a flow diagram illustrating the research strategy and selection procedure.

All five studies (6, 15-18) were RCTs published in peerreviewed journals. One trial compared RIB to no block, while another compared RIB to both no block and type-II pectoral nerve block (PECS). A third trial compared RIB with no block and the serratus anterior plane block (SAPB), while a fourth compared RIB with no block and the erector spinae plane block. The final trial compared RIB with no block and the rhomboid intercostal and subserratus plane block (RISS). Each of these comparisons was analyzed independently. Table 1 provides a summary of the specific features of the included studies and the GRADE results are summarized in Table 2. A risk of bias assessment using RoB 2.0 showed that all studies had a low risk of bias (Figure 3).

4.1. Primary Outcome

For the assessment of postoperative pain, two studies utilized NRS scores (6, 15), while three studies used VAS scores (16-18). Since NRS and VAS scores are comparable, the VAS scores were converted to NRS values for consistency in comparison (19).

4.2. Numerical Rating Scale Scores at Rest Recorded 1 h Postsurgery

A forest plot was created to compare NRS scores at rest one hour post-surgery for patients receiving RIB versus no block, based on the results of four studies



Figure 2. PRISMA Flow diagram of included and excluded studies

Table 1. Studies Char	acteristi	с						
Authors	Year	Study Design	Country	Number of Patients	Mean Ages	Type of Surgery	RIB Dose	Opioid
Elhouty et al. (17)	2023	RCT	Egypt	142: RIB (71); control (71)	RIB: 23.2 ± 4.25; control: 23.7 ± 4.1	VATS	20 mL 0.25% bupivacaine	Fentanyl
Şimek et al. (18)	2022	RCT	Turkey	50: RIB (25); control (25)	RIB: 60.2 ± 10.2; control: 54.8 ± 12.2	Elective resection of non-metastatic lung malignancies	20 mL 0.25% bupivacaine	Tramadol
Ciftci et al. (16)	2021	RCT	Turkey	60: RIB (30); control (30)	RIB: 49.4 ± 3.7; control: 43.1 ± 4.2	Unilateral BCS-AD and axillary dissection surgery	30 mL 0.25% bupivacaine	Fentanyl
Deng et al. (6)	2021	RCT	China	60: RIB (30); control (30)	RIB: 60.5 ± 11.6; control: 56.6 ± 11.5	VATS	20 mL 0.375% ropivacaine	Sufentanil
Altipamark et al. (15)	2020	RCT	Turkey	56: RIB (28); control (28)	RIB: 53.8 ± 11.2; control: 52.0 ± 11.5	Unilateral Modified Radical Mastectomy	30mL 0.25% bupivacaine	Morfin

Abbreviation: RIB, rhomboid intercostal block.

(Figure 4) (6, 15, 17, 18). The analysis utilized a fixedeffects model. As shown in Figure 3, the total number of patients across these four studies was 308, with 154 patients in the RIB group and 154 in the control group. The results indicated that RIB significantly reduced NRS scores at rest one hour post-surgery compared to the no block group (SMD=-1.33; 95% CI=-1.74 to -0.91; P < 0.00001, $I^2 = 18\%$, P = 0.27).

Outcomes	No. of Participants (Studies)	Certainty of the Evidence (GRADE)	Comments
1 h NRS score	308 (4 RCTs)	$\oplus \oplus \oplus \oplus$ (high)	
6 h NRS score	308 (4 RCTs)	$\bigoplus \bigoplus \bigcirc$ (moderate)	Inconsistency" was downgraded to "serious."
12 h NRS score	252 (3 RCTs)	$\oplus \oplus \oplus \oplus$ (high)	
24 h NRS score	368 (5 RCTs)	$\bigoplus \bigoplus \bigcirc$ (moderate)	Inconsistency" was downgraded to "serious."
24 h opoid consumption	368 (5 RCTs)	$\bigoplus \bigoplus \bigcirc$ (moderate)	Inconsistency" was downgraded to "serious."
PONV	226 (4 RCTs)	$\oplus \oplus \oplus \oplus$ (high)	

Abbreviations: GRADE, grades of recommendation, assessment, development, and evaluation; RCTs, randomized controlled trials.



Figure 3. Risk of bias 2.0. of randomized controlled trials (RCTs). Green circle, low risk of bias; yellow circle, unclear risk of bias; red circle, high risk of bias.

4.3. Numerical Rating Scale Scores at Rest Recorded 6h Postsurgery

The forest plot (Figure 4) illustrates the comparison of NRS scores at rest six hours post-surgery between RIB and no block. This analysis, based on data from four studies (6, 15, 17, 18) and employing a random-effects model, revealed considerable heterogeneity across trials, even after conducting sensitivity analyses that excluded individual studies one by one. The total number of patients in these four studies was 308, with 154 in the RIB group and 154 in the control group. The results indicated that RIB did not lead to a statistically significant reduction in NRS scores at rest six hours

NRS Scores in 1h Post-surgery

		RIB		No	Block	t I		Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Altiparmak, et al., 2020	1.64	0.78	28	2	0	28		Not estimable	2020	
Wei Deng, et al., 2021	0.16	0.38	30	0.8	0.43	30	51.3%	-1.56 [-2.14, -0.97]	2021	_
Şimek, et al., 2022	2	0.51	25	3.26	1.53	25	48.7%	-1.09 [-1.68, -0.49]	2022	_ _
Elhouty, et al., 2023	0	0	71	1.35	0.76	71		Not estimable	2023	
Total (95% CI)	df = 1 (P - 0 '	154	19%		154	100.0%	-1.33 [-1.74, -0.91]		→
Test for overall effect: Z = 6	6.24 (P =	0.000	101)	10.0						-2 -1 0 1 2 RIB No Block

NRS Scores in 6h Post-surgery

		RIB		No	Block	L L	1	Std. Mean Difference			Std. M	lean Differ	ence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year		IV, R	andom, 95	5% CI	
Altiparmak, et al., 2020	2.36	0.78	28	2.36	0.78	28	25.1%	0.00 [-0.52, 0.52]	2020			+		
Wei Deng, et al., 2021	1.63	0.56	30	2.03	0.18	30	25.1%	-0.95 [-1.48, -0.41]	2021		-			
Şimek, et al., 2022	2.26	1.01	25	3.75	1.45	25	24.9%	-1.17 [-1.78, -0.57]	2022			-		
Elhouty, et al., 2023	0.65	0.51	71	4.2	1.14	71	25.0%	-4.00 [-4.57, -3.42]	2023					
Total (95% CI)			154			154	100.0%	-1.53 [-3.21, 0.15]			-			
Heterogeneity: Tau ² = 2.87	Chi ² =	109.0	5, df = 3	3 (P < 0.	00001); l ^x = 9	7%			-4	-2	Ó	2	4
Test for overall effect: $Z = 1$	1.78 (P=	: 0.08)										RIB No E	Block	

NRS Scores in 12h Post-surgery

		RIB		No	Block	r.		Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Altiparmak, et al., 2020	2.36	0.78	30	2.64	0.78	30	25.2%	-0.35 [-0.86, 0.16]	2020	
Şimek, et al., 2022	2.26	1.53	25	3.26	1.02	25	19.8%	-0.76 [-1.33, -0.18]	2022	
Elhouty, et al., 2023	2.42	0.97	71	3.27	0.89	71	54.9%	-0.91 [-1.25, -0.56]	2023	
Total (95% CI)			126			126	100.0%	-0.74 [-0.99, -0.48]		◆
Heterogeneity: Chi ² = 3.11 Test for overall effect: Z = 5	, df = 2 (5.65 (P <	(P = 0.) < 0.000	21); I*= 001)	36%						-1 -0.5 0 0.5 1 RIB No Block

NRS Scores in 24h Post-surgery

		RIB		No	Block	1		Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Altiparmak, et al., 2020	0.64	0.78	28	1.36	0.78	28	25.4%	-0.91 [-1.46, -0.36]	2020	
Ciftci, et al., 2021	0	0	30	0.36	0.78	30		Not estimable	2021	
Wei Deng, et al., 2021	2.13	0.34	30	3.27	0.45	30	23.8%	-2.82 [-3.55, -2.09]	2021	_ _
Şimek, et al., 2022	1	0.51	25	3.13	1.27	25	24.0%	-2.17 [-2.88, -1.46]	2022	
Elhouty, et al., 2023	3.73	0.72	71	4.24	0.62	71	26.9%	-0.76 [-1.10, -0.41]	2023	-
Total (95% CI)			184			184	100.0%	-1.62 [-2.56, -0.69]		-
Heterogeneity: Tau* = 0.81	Chi*=	33.83	df = 3	(P < 0.0	0001)	* = 91	%			-2 -1 0 1 2
Test for overall effect: Z = 3	3.42 (P =	: U.UUU	16)							RIB No Block

Overall 24h Post-surgery Opioid Consumption

		RIB		No	Block			Std. Mean Differen	nce		Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95	% CI 1	'ear	IV, Random, 95% CI	
Altiparmak, et al., 2020	52.5	9.01	28	102.5	14.6	28	20.5%	-4.06 [-5.00, -3	3.12] 2	020	+	
Ciftci, et al., 2021	30	5.77	30	95	5.74	30	15.9%	-11.15 [-13.27, -9	9.02] 2	021		
Wei Deng, et al., 2021	58	3.4	30	73.5	8.2	30	21.2%	-2.44 [-3.12, -1	1.76] 2	021	-	
Şimek, et al., 2022	77.3	19.1	25	136	29.3	25	21.1%	-2.34 [-3.07, -1	1.60] 2	022	-	
Elhouty, et al., 2023	47.1	8.47	71	108	18.9	71	21.4%	-4.14 [-4.72, -3	3.55] 2	023	•	
Total (95% CI)			184			184	100.0%	-4.49 [-6.09, -2	2.90]		•	
Heterogeneity: Tau ² = 3.01	; Chi ² =	74.77	df = 4	(P < 0.00	0001); I	² = 959	%				-10 -5 0 5 1	0
Test for overall effect: $Z = 5$	0.52 (P <	0.001	JU1)								RIB No Block	
PONV												
		RIB		No Blo	ock			Risk Ratio			Risk Ratio	
Study or Subgroup	Eve	nts	Total	Events	Total	Wei	ight M	-H, Fixed, 95% CI	Year		M-H, Fixed, 95% Cl	
Altiparmak, et al., 2020		2	28	6	28	10	.9%	0.33 [0.07, 1.51]	2020			
Ciftci, et al., 2021		6	30	25	30	45	.5%	0.24 [0.12, 0.50]	2021			
Wei Deng, et al., 2021		5	30	17	30	30	.9%	0.29 [0.12, 0.69]	2021			
Şimek, et al., 2022		3	25	7	25	12	.7%	0.43 [0.12, 1.47]	2022			
Total (95% CI)			113		113	100	.0%	0.29 [0.18. 0.47]			•	
Total events		16		55							-	
Heterogeneity Chi ² = 0.6	67 df=	3 (P :	= 0.881	1 ² = 0%						-		
neterogeneity. offr = 0.0	, ai -	~ 11 .	- 0.00)							0.01	01 1 10	100
Toot for overall offect: 7 -	- 6 0 4 /	D ~ 0	00001	13						0.01	0.1 1 10	100

Figure 4. Forest plot of the primary and secondary outcomes. Squares show the SMD and OR estimates for each study, and the lines that cross them show the 95% confidence interval. The overall pooled estimate is shown by the diamond. SMD, standardized mean difference; RR, relative risk; CI, confidence interval; IV, inverse variance; M–H, mantel Haenszel; SD, standard deviation; RIB, rhomboid intercostal block.

post-surgery compared to the no block group (SMD = -1.53; 95% CI = -3.21 to 0.15; P = 0.08, $I^2 = 97\%$, P < 0.00001).

4.4. Numerical Rating Scale Scores at Rest Recorded 12h Postsurgery The forest plot (Figure 4) displays the comparison of NRS scores at rest 12 hours post-surgery for RIB versus no block based on three studies (15, 17, 18). A fixed-effects model was applied for this analysis, encompassing a total of 252 patients—126 in the RIB group and 126 in the control group. The findings showed a significant reduction in NRS scores at rest at 12 hours post-surgery

for the RIB group compared to the no block group (SMD = -0.74; 95% CI = -0.99 to -0.48; P < 0.00001, $I^2 = 36\%$, P = 0.21).

4.5. Numerical Rating Scale Scores at Rest Recorded 24h Postsurgery

The forest plot (Figure 4) illustrates the comparison of NRS scores at rest 24 hours post-surgery for RIB versus no block, based on five studies (6, 15-18). A randomeffects model was applied, revealing significant heterogeneity between trials despite sensitivity analyses that omitted individual studies alternately. The total number of patients included across these five studies is 368, with 184 patients in both the RIB and control groups. The analysis demonstrated a significant reduction in NRS scores at rest 24 hours post-surgery for the RIB group compared to the no block group (SMD

=-1.62; 95% CI=-2.56 to -0.69; P=0.0006, $I^2 = 91\%$, P< 0.00001).

4.6. Secondary Outcomes

4.6.1. Overall 24 h Post-surgery Opioid Consumption

In terms of postoperative opioid consumption, two studies utilized fentanyl (16, 17), one used morphine (15), one used tramadol (18), and one used sufentanil (6). To standardize the data, the morphine, tramadol, and sufentanil doses were converted to fentanyl equivalents (20). However, the study using sufentanil was excluded from the analysis as its converted fentanyl dose was significantly lower than in the other groups, which could skew the results.

The forest plot (Figure 4) presents opioid consumption within 24 hours post-surgery. A randomeffects model was applied to calculate the overall opioid consumption, and sensitivity analysis showed that even after omitting individual studies alternately, significant heterogeneity persisted between trials. Across the four remaining studies, 368 patients were included, with 184 in both the RIB and control groups. The analysis revealed that RIB significantly reduced opioid consumption within 24 hours post-surgery compared to the no block group (SMD = -4.49; 95% CI = -6.09 to -2.90; P < 0.00001, $I^2 = 95\%$, P < 0.00001).

4.6.2. Postoperative Nausea and Vomitting

In four studies, the rates of PONV related to opioid use were assessed (6, 15, 16, 18). The results are depicted in the forest plot (Figure 4). A fixed-effects model was used for the analysis. The total number of patients across these four studies was 226, with 113 in the RIB group and 113 in the control group. The analysis demonstrated that RIB significantly reduced PONV rates compared to the no block group (RR = 0.29; 95% CI = 0.18 to 0.45° P = 0.0001 I^2 = 0.0001 I^2

to 0.47; P < 0.00001, $I^2 = 0\%$, P = 0.88).

5. Discussion

This meta-analysis, encompassing five RCTs with a total of 368 patients, evaluated the analgesic effectiveness and safety of RIB in patients undergoing thoracic and breast surgical procedures. Compared to the control group, RIB significantly reduced pain scores at rest at various time points and markedly decreased opioid consumption during the first 24 hours postsurgery. Additionally, RIB was associated with a lower incidence of PONV.

While thoracic epidural analgesia (TEA) has long been considered the gold standard for RA following thoracic and breast surgeries, it comes with certain risks (21, 22). These include complications such as spinal abscess, dural puncture, epidural hematoma, and significant hemodynamic effects due to sympathetic blockade from local anesthesia (18).

Rhomboid intercostal block is a novel interfascial plane block administered in the area along the medial border of the scapula, known as the triangle of auscultation (7, 23). Previous cadaveric investigations using methylene blue contrast have shown that the dye spreads between the rhomboid major and intercostal muscles from the T2 to T8 levels, both cranially and caudally. Additionally, staining was observed in the posterior rami of the thoracic spinal nerves at T2-T9 levels and the lateral cutaneous branches of the intercostal nerves from T2 to T8 (7, 18) This suggests that RIB can provide effective analgesia for both the anterior and posterior hemithorax, making it suitable for thoracic and breast surgical procedures.

The RIB group significantly reduced pain levels at rest compared to the no block group at one, 12, and 24 hours post-surgery, based on NRS scores. Additionally, the RCTs included in this meta-analysis compare the RIB group with other block techniques. RIB was shown to be superior to the serratus anterior plane block (SAPB) due to its association with better analgesic outcomes (17). However, other studies found that RIB provided similarly effective analgesia when compared to the erector spinae plane block (ESPB) and type-II pectoral nerve block (PECS II) (16, 18). While neither PECS II nor RIB is superior to the other, the PECS II block has the disadvantage of having puncture points near the surgical site (15).

of 24-hour postoperative opioid In terms consumption, the RIB group consumed significantly fewer opioids than the no block group. This reduction in opioid use may offer potential benefits by decreasing opioid-related adverse effects, such as bronchoconstriction at high doses, cough suppression, chest wall rigidity, and dose-dependent respiratory depression (24). Additionally, lower opioid doses can reduce the risk of opioid-induced hyperalgesia (OIH), a condition where patients using opioids for pain management become more sensitive to painful stimuli, leading to poorly controlled pain and the need for higher doses (25, 26). In summary, reduced opioid consumption may contribute to improved recovery during the postoperative period.

In terms of one of the most common opioid-related complications, namely PONV, the RIB group showed an incidence of 14.16%, whereas the no block group had a significantly higher incidence of 48.67%. Opioids can induce PONV by directly affecting receptors in the brainstem's chemoreceptor trigger zone (27). Postoperative opioid use typically increases the risk of PONV in a dose-dependent manner, with the effect persisting as long as opioids are administered (28). Although PONV may be transient or mild, its impact on patients can be severe, leading to delayed recovery, difficulties with mobilization, and reduced oral intake (29). The lower incidence of PONV in the RIB group may be attributed to the minimal opioid consumption within 24 hours post-surgery. None of the studies in this meta-analysis reported any block-related complications. Therefore, it can be concluded that RIB is a relatively safe blocking technique.

It is important to acknowledge several limitations of this meta-analysis. First, despite using a random-effects model and applying strict inclusion and exclusion criteria to standardize the selected studies, there remains significant heterogeneity in the results. Sensitivity analyses demonstrated that even when individual studies were alternately omitted, a considerable amount of heterogeneity persisted among the RCTs. The primary causes of this heterogeneity may include variations in injection levels, agent concentrations, and volumes. However, conducting a meta-regression to assess the impact of these potential variables was not feasible due to the limited number of available studies.

Second, the studies included in this analysis had relatively small sample sizes, which may limit the strength of the conclusions. Larger, multicenter RCTs are needed to further investigate and solidify the findings in this area. Finally, there is always some uncertainty when pooling data for a meta-analysis, particularly when transforming median and range values into mean and SD values, which can introduce additional variability into the effect size estimates.

In conclusion, this meta-analysis demonstrated that the RIB group experienced significantly lower NRS scores, reduced 24-hour opioid consumption, and lower rates of PONV compared to the no block group. Future RCTs with more standardized reporting are essential to validate and expand upon the findings of previous studies and this meta-analysis.

Footnotes

Authors' Contribution: Study concept and design: T. S., D. S., and W. I. N.; acquisition of data: T. S., D. S., and W. I. N.; analysis and interpretation of data: T. S., D. S., and W. I. N.; drafting of the manuscript: T. S.; critical revision of the manuscript for important intellectual content: D. S., and W. I. N.; statistical analysis: T. S.; administrative, technical, and material support: D. S. and W. I. N.; study supervision: D. S. and W. I. N.

Conflict of Interests Statement: The authors declared no conflict of interests.

Data Availability: The data presented in this study are uploaded during submission as a supplementary file and are openly available for readers upon request.

Funding/Support: The authors received no financial support for the research, authorship, and/or publication of this article. All publication costs are borne by the authors.

References

- Chen R, Su S, Shu H. Efficacy and safety of rhomboid intercostal block for analgesia in breast surgery and thoracoscopic surgery: a metaanalysis. *BMC Anesthesiol.* 2022;22(1):71. [PubMed ID: 35296252]. [PubMed Central ID: PMC8925179]. https://doi.org/10.1186/s12871-022-01599-4.
- Goto T. What is the best pain control after thoracic surgery? J Thorac Dis. 2018;10(3):1335-8. [PubMed ID: 29708130]. [PubMed Central ID: PMC5906229]. https://doi.org/10.21037/jtd.2018.03.63.
- Eroglu A, Erturk E, Apan A, Apan OC. Regional anesthesia for postoperative pain control. *Biomed Res Int.* 2014;2014:309606.
 [PubMed ID: 25054137]. [PubMed Central ID: PMC4087300]. https://doi.org/10.1155/2014/309606.
- 4. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain.

2016;**17**(2):131-57. [PubMed ID: 26827847]. https://doi.org/10.1016/j.jpain.2015.12.008.

- Chen YK, Boden KA, Schreiber KL. The role of regional anaesthesia and multimodal analgesia in the prevention of chronic postoperative pain: a narrative review. *Anaesthesia*. 2021;**76 Suppl** 1(Suppl 1):8-17. [PubMed ID: 33426669]. [PubMed Central ID: PMC8369227]. https://doi.org/10.1111/anae.15256.
- Deng W, Hou XM, Zhou XY, Zhou QH. Rhomboid intercostal block combined with sub-serratus plane block versus rhomboid intercostal block for postoperative analgesia after video-assisted thoracoscopic surgery: a prospective randomized-controlled trial. *BMC Pulm Med.* 2021;21(1):68. [PubMed ID: 33632189]. [PubMed Central ID: PMC7908696]. https://doi.org/10.1186/s12890-021-01432-7.
- Elsharkawy H, Saifullah T, Kolli S, Drake R. Rhomboid intercostal block. *Anaesthesia*. 2016;**71**(7):856-7. [PubMed ID: 27291611]. https://doi.org/10.1111/anae.13498.
- 8. Okmen K. Efficacy of rhomboid intercostal block for analgesia after thoracotomy. *Korean J Pain*. 2019;**32**(2):129-32. [PubMed ID: 31091512]. [PubMed Central ID: PMC6549589]. https://doi.org/10.3344/kjp.2019.32.2.129.
- Elsharkawy H, Hamadnalla H, Altinpulluk EY, Gabriel RA. Rhomboid intercostal and subserratus plane block -a case series. *Korean J Anesthesiol*. 2020;73(6):550-6. https://doi.org/10.4097/kja.19479.
- Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. [PubMed ID: 25554246]. [PubMed Central ID: PMC4320440]. https://doi.org/10.1186/2046-4053-4-1.
- Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;**366**:l4898. [PubMed ID: 31462531]. https://doi.org/10.1136/bmj.l4898.
- Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94. [PubMed ID: 21195583]. https://doi.org/10.1016/j.jclinepi.2010.04.026.
- Rover C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies. *BMC Med Res Methodol*. 2015;**15**:99. [PubMed ID: 26573817]. [PubMed Central ID: PMC4647507]. https://doi.org/10.1186/s12874-015-0091-1.
- IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. *BMC Med Res Methodol.* 2014;14:25. [PubMed ID: 24548571]. [PubMed Central ID: PMC4015721]. https://doi.org/10.1186/1471-2288-14-25.
- Altiparmak B, Korkmaz Toker M, Uysal AI, Dere O, Ugur B. Evaluation of ultrasound-guided rhomboid intercostal nerve block for postoperative analgesia in breast cancer surgery: a prospective, randomized controlled trial. *Reg Anesth Pain Med*. 2020;**45**(4):277-82. [PubMed ID: 32079739]. https://doi.org/10.1136/rapm-2019-101114.
- Ciftci B, Ekinci M, Basim P, Celik EC, Tukac IC, Zenciroglu M, et al. Comparison of Ultrasound-Guided Type-II Pectoral Nerve Block and Rhomboid Intercostal Block for Pain Management Following Breast Cancer Surgery: A Randomized, Controlled Trial. *Pain Pract.* 2021;21(6):638-45. [PubMed ID: 33710724]. https://doi.org/10.1111/papr.13004.
- 17. Elhouty MG, Elbahrawy K, Elawady MS. Rhomboid intercostal block versus serratus block for postoperative analgesia after thoracoscopic

sympathectomy for primary palmar hyperhidrosis: a randomized controlled trial. *BMC Anesthesiol*. 2023;**23**(1):241. [PubMed ID: 37468840]. [PubMed Central ID: PMC10355006]. https://doi.org/10.1186/s12871-023-02203-z.

- Simek T, Geyik F, Simsek A, Yuce Y, Saracoglu K, Demirhan R. Ultrasound-guided erector spinae plane block versus rhomboid intercostal block for postoperative analgesia following thoracotomy. *Ann Clin Analytical Med.* 2022;**13**(8). https://doi.org/10.4328/acam.21189.
- Thong ISK, Jensen MP, Miro J, Tan G. The validity of pain intensity measures: what do the NRS, VAS, VRS, and FPS-R measure? *Scand J Pain*. 2018;18(1):99-107. [PubMed ID: 29794282]. https://doi.org/10.1515/sjpain-2018-0012.
- Tan S, Lee E, Lee S, Sakaria SS, Roh JS. Morphine Equianalgesic Dose Chart in the Emergency Department. *J Educ Teach Emerg Med*. 2022;7(3):L1-L20. [PubMed ID: 37465775]. [PubMed Central ID: PMC10332699]. https://doi.org/10.21980/J8RD29.
- 21. Deepshika R, Parameswari A, Venkitaraman B, Vakamudi M, Manickam A. A Randomized Clinical Study to Compare the Perioperative Analgesic Efficacy of Ultrasound-Guided Erector Spinae Plane Block Over Thoracic Epidural in Modified Radical Mastectomy. *Cureus*. 2023;**15**(12). e51103. [PubMed ID: 38149062]. [PubMed Central ID: PMC10750254]. https://doi.org/10.7759/cureus.51103.
- Kelsheimer B, Williams C, Kelsheimer C. New Emerging Modalities to Treat Post-Thoracotomy Pain Syndrome: A Review. *Mo Med.* 2019;**116**(1):41-4. [PubMed ID: 30862984]. [PubMed Central ID: PMC6390789].
- 23. Toulan HF, Abdelrazik RA. Effects of rhomboid intercostal plane block for postoperative analgesia after thoracoscopic surgery compared with local anesthetic infiltration: A randomized clinical trial. *Egypt J Anaesthesia*. 2022;**38**(1):179-84. https://doi.org/10.1080/11101849.2022.2059611.
- Evrard E, Motamed C, Pages A, Bordenave L. Opioid Reduced Anesthesia in Major Oncologic Cervicofacial Surgery: A Retrospective Study. J Clin Med. 2023;12(3). [PubMed ID: 36769551]. [PubMed Central ID: PMC9917718]. https://doi.org/10.3390/jcm12030904.
- Vargas-Schaffer G, Paquet S, Neron A, Cogan J. Opioid Induced Hyperalgesia, a Research Phenomenon or a Clinical Reality? Results of a Canadian Survey. *J Pers Med.* 2020;**10**(2). [PubMed ID: 32326188]. [PubMed Central ID: PMC7354508]. https://doi.org/10.3390/jpm10020027.
- Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia. *Lancet*. 2019;**393**(10180):1558-68. [PubMed ID: 30983591]. https://doi.org/10.1016/S0140-6736(19)30430-1.
- 27. Zhang Z, Li C, Xu L, Sun X, Lin X, Wei P, et al. Effect of opioid-free anesthesia on postoperative nausea and vomiting after gynecological surgery: a systematic review and meta-analysis. *Front Pharmacol.* 2023;**14**:1330250. [PubMed ID: 38239201]. [PubMed Central ID: PMC10794765]. https://doi.org/10.3389/fphar.2023.1330250.
- Sun Q, Zhang C, Liu S, Lv H, Liu W, Pan Z, et al. Efficacy of erector spinae plane block for postoperative analgesia lumbar surgery: a systematic review and meta-analysis. *BMC Anesthesiol*. 2023;23(1):54.
 [PubMed ID: 36797665]. [PubMed Central ID: PMC9933390]. https://doi.org/10.1186/s12871-023-02013-3.
- Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. *Anesth Analg.* 2020;**131**(2):411-48. [PubMed ID: 32467512]. https://doi.org/10.1213/ANE.000000000004833.